Outcome comparison of pyrotinib with current standard of care in the second/third line setting in advanced non-small cell lung cancer patients with HER2 mutation
暂无分享,去创建一个
S. Ren | Caicun Zhou | G. Gao | Xue-Fei Li | Chao Zhao | Xiaoxia Chen | Libo Luo | C. Su | F. Zhou | Keyi Jia | Bin Chen | Yan Wang | Fengying Wu | C. Shao | Yiwei Liu | Lei Cheng | Shuo Yang | S. Mao | Wan-zhong Wang | Xinyu Liu | Jia Yu